The UK’s Competition and Markets Authority (CMA) has received a £23m ($29m) offer from Vifor Pharma for the NHS to address competition concerns that the regulator has been investigating.

Vifor Pharma has agreed to pay £23m to the NHS after being accused by Britain's competition watchdog of making false safety claims about a competitor's iron deficiency treatment. The Competition ...

After recently taking steps to undo messaging about a rival product in the EU, CSL Vifor is carrying its amends campaign west to the U.K. Following an investigation launched earlier this year by ...

INR:5940. england cricket team vs australia cricket team match scorecard Analysis of a study of 950,000 participant ...

Vifor Pharma, a part of Switzerland-based Galenica Group (SIX: GALN) develops pharmaceutical products for the treatment of iron deficiency. Vifor Pharma, a part of Switzerland-based Galenica Group ...

Patiromer sorbitex calcium is under clinical development by Vifor Pharma Management and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase II ...

Concurrently with the merger deal, Cara has also agreed to an asset purchase agreement with Vifor Fresenius Medical Care Renal Pharma, Ltd., a company jointly owned by Fresenius Medical Care and ...

Vifor Pharma has forged a strategic partnership with Fresenius Kabi, focusing on marketing a portfolio of iron deficiency drugs. The partnership expands Vifor Pharma’s cooperation with Fresenius ...

Concurrently, the duo disclosed an asset purchase agreement with Vifor Fresenius Medical Care Renal Pharma (CSL Vifor), a company owned by German dialysis company Fresenius Medical Care (FMS ...